Needham analyst Gil Blum has maintained their neutral stance on STTK stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum’s rating is based on several factors, primarily the early stage of Shattuck Labs’ development pipeline. The company is progressing with its DR3 targeting monoclonal antibody, SL-325, but it remains in the preliminary phases with IND clearance anticipated soon and initial clinical results expected in 2026. This timeline suggests that significant milestones are still ahead, and the focus will initially be on early safety data and dose selection.
Additionally, while preclinical results have shown promise, demonstrating safety in non-human primates and the potential for infrequent dosing, the real-world application in humans is yet to be established. Financially, Shattuck Labs has a solid runway with $51 million in cash and a recent financing boost, which extends their operational capacity into 2029. However, given the uncertainties and the nascent stage of their projects, a Hold rating is deemed appropriate at this time.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.